A-319 is under clinical development by ITabMed and currently in Phase I for Systemic Lupus Erythematosus. According to GlobalData, Phase I drugs for Systemic Lupus Erythematosus have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how A-319’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
A-319 overview
A-319 is under development for the treatment of B cell malignancies including B-cell acute lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, systemic lupus erythematosus, mantle cell lymphoma. The therapeutic candidate is a Bi-specific T-cell engager (BiTE) antibody that acts by targeting CD3 and cells expressing B lymphocyte antigen CD19. It is administered as an intravenous infusion. It is developed based on Immunotherapy antibody (ITab) technology platform. It was under development for the treatment of chronic lymphocytic leukemia.
ITabMed overview
ITabMed focuses on the research and development of tumor immunotherapy products for the treatment of cancer. It is headquartered in Shanghai City, Shanghai, China.
For a complete picture of A-319’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.